Pre-IPO investment opportunity — Phase 3 now open

The merger is underway.
The IPO is next.

ReGen Therapeutics is merging with Futurum Group — a media and entertainment company with independently valued IP, global distribution and a clear pathway to a public listing in 2026.

£74m

Valuation

£0.74

£0.59

Market price → your price

20%

Discount on entry

ca £100m

Expected IPO listing valuation

The story so far

A merger built on solid foundations

Initial discussions began in mid-2025. Agreements were signed in January 2026 and work began in earnest from that point. Here is where we have been and where we are going.

November 2025

Merger announced

ReGen Therapeutics and Futurum Group announce a proposed merger, creating a combined entity with a clear IPO pathway. The deal structure is published including the Rights Issue, goodwill share pool and bonus warrant terms.

Complete

March – June 2026

Phase 1 & 2 Rights Issue

The Rights Issue opens to existing ReGen shareholders. Over 1,500 registrations received. Phase 1 and Phase 2 close with strong shareholder participation, on target to raise £1.2m from the existing base.

Complete

July 2026 onwards

Phase 3 & IPO preparation

Phase 3 opens to external investors. The IPO advisory team is appointed in parallel. Due diligence, listing documentation and the broker bookbuild begin. A listing on AIM or the LSE is targeted for September to October 2026.

In progress

About Futurum Group

The company behind the opportunity

Futurum Group is a media and entertainment company built around a portfolio of premium animated IP assets, with active global distribution and a Web3 gaming venture in development.

Current valuation of £74m is based on independently assessed IP value and active commercial contracts. The company is targeting a public listing at an estimated valuation of approximately £100m.

Visit futurumgroup.info →

🎬

Five premium animation IP assets

Independently valued at circa $90m US, led by Paddles with rapidly expanding global broadcast and distribution.

🌐

International distribution

Active merchandising and distribution contracts across multiple territories.

🔗

Web3 educational gaming

A premium educational gaming platform featuring the much-loved characters from Futurum's IP portfolio at its heart.

Videos

Hear from the team directly

Meet Paddles - The worlds most huggable Polar bear and see our educational gaming venture in action.

Meet Paddles - The worlds most huggable Polar bear

An introduction to Futurum Group

In this short video, Francis Fitzpatrick, CEO of Futurum Group, introduces the company, the world-class IP portfolio and our exciting plans for the educational gaming platform. We think you will find it well worth a few minutes of your time.

Phase 3 investment terms

The same terms. A wider door.

Phase 3 is open to external investors on exactly the same privileged terms as existing shareholders. First come, first served.

Entry price per share

£0.592

vs £0.74 current market price

Discount to market

20%

immediate uplift on entry

Bonus shares

59.8%

of subscribed shares, free

Bonus warrants

1:3 ratio

one warrant per 3 shares

Warrant strike price

1.2× IPO

exercisable for 24 months post-listing

Refer a friend bonus

bonus shares on their investment

Illustrative returns based on current market price of £0.74 per share. Not financial advice.

£5,000investment

Shares at £0.592

8,446

Bonus shares

+5,051

Total shares

13,497

Warrants

2,815

Value at £0.74

£9,988

£25,000investment

Shares at £0.592

42,230

Bonus shares

+25,254

Total shares

67,484

Warrants

14,077

Value at £0.74

£49,938

£50,000investment

Shares at £0.592

84,459

Bonus shares

+50,506

Total shares

134,965

Warrants

28,153

Value at £0.74

£99,874

The team

The people delivering this

Timothy Shilton

CEO, ReGen

CEO of ReGen Therapeutics and public face of the merger, leading all shareholder communications.

Francis Fitzpatrick

CEO, Futurum

Founder and CEO of Futurum Group, responsible for IP portfolio, commercial strategy and investor relations.

Martin Regan

Head of Web3

Head coordinator of the merger and Web3 strategy lead for the combined group.

Christopher Lyster

Equity Investment

Leads investor relations and equity investment on the Futurum side.

Norman Lott

CFO, ReGen

Oversees financial management, share registry, reporting and nominee structure coordination.

Tobias Kirmes

Portal Operations

Manages shareholder communications, portal operations and day-to-day investor support.

Phillip Legg

Head of IT

Built and maintains the investor portal and all digital infrastructure supporting the raise.

Barnaby Procopiou

Advisor

Strategic advisor in equity investment and corporate development.

Lucas

IT Support

Jen

Portal Support

Steff

Portal Support

Paddles

Chief Entertainer

Questions & answers

Common questions

If you cannot find what you are looking for, contact us at info@regentherapeutics.uk

What is the Rights Issue and how does it work?+

The Rights Issue allows investors to subscribe for new Futurum Group shares at a discounted price of £0.592, which represents a 20% discount to the current market price of £0.74. For every share you subscribe for, you also receive bonus shares (59.8% of your subscription, free of charge) and warrants (one for every three shares subscribed). Warrants give you the right to purchase additional shares at a fixed price post-IPO.

What are bonus warrants and how do they work?+

Bonus warrants are issued at a ratio of 1:3 — one warrant for every three shares you subscribe for. Each warrant gives you the right (but not the obligation) to purchase additional Futurum Group shares at a strike price of 1.2 times the IPO share price, for a period of 24 months from the date of listing.

When is the IPO expected and what is the target valuation?+

We are targeting a listing on AIM or the London Stock Exchange in September to October 2026. The estimated IPO valuation is approximately £100m, based on approximately 10–15% dilution at the point of listing. This is an indicative range and is subject to market conditions and the bookbuild outcome.

Can I sell my shares before the IPO?+

No. The shares are illiquid until the point of listing. There is no open market for these shares prior to IPO. The listing is what creates the liquidity event for investors.

What is the minimum investment?+

The minimum investment is one share at £0.592. There is no upper limit on Phase 3 participation, and you are welcome to submit multiple applications if you wish to invest in stages.

How does the referral programme work?+

Once you are registered, you will receive a unique referral code. Share it with friends or family who go on to invest, and you will receive a 5% bonus in additional Futurum Group shares based on the value of their investment. There is no limit to the number of referrals you can make.

What are the risks of investing?+

This is a pre-IPO investment and carries risk. The IPO is a target and not a guarantee. Valuations are indicative and the actual share price at listing will be set by the market. Your investment is illiquid until listing and the value of your shares can go down as well as up. We strongly recommend taking independent financial advice before committing.

Important — investment risks

Capital is at risk. This is a pre-IPO investment. The value of your investment can go down as well as up and you may get back less than you put in. The IPO is a target and not a guarantee. Shares are illiquid until listing and there is no mechanism to sell prior to that point. Valuations are indicative and subject to market conditions. If you are in any doubt, please seek independent financial advice before committing.

This page is for information purposes only and does not constitute financial advice or an offer to invest. ReGen Therapeutics Limited is registered in England & Wales. Registration No. 07476879. Futurum Group (FGI Media Limited). If you are in any doubt, seek independent financial advice.

The merger is underway. The IPO is next.

The merger is underway.
The IPO is next.